Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Jonathan C, Javitt"'
Autor:
Andrew Nierenberg, Philip Lavin, Daniel C. Javitt, Richard Shelton, Michael T. Sapko, Sanjay Mathew, Robert E. Besthof, Jonathan C. Javitt
Publikováno v:
International Journal of Bipolar Disorders, Vol 11, Iss 1, Pp 1-10 (2023)
Abstract Background We tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloseri
Externí odkaz:
https://doaj.org/article/c669ab8bd149461a97bbf2474ba28343
Publikováno v:
Antibiotics, Vol 13, Iss 4, p 308 (2024)
D-Cycloserine (DCS) is a broad-spectrum antibiotic that is currently FDA-approved to treat tuberculosis (TB) disease and urinary tract infection (UTI). Despite numerous reports showing good clinical efficacy, DCS fell out of favor as a UTI treatment
Externí odkaz:
https://doaj.org/article/ffbd6c0f170e475cb01e7ab373362ce1
Autor:
Jihad Georges Youssef, MD, Mohammad Z. Bitar, MD, Faisal Zahiruddin, DO, Mukhtar Al-Saadi, MD, EdD, Mahmoud Elshawwaf, MD, Simon Yau, MD, Ahmad Goodarzi, MD, Jonathan C. Javitt, MD, MPH
Publikováno v:
Critical Care Explorations, Vol 4, Iss 1, p e0607 (2022)
BACKGROUND:. Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broa
Externí odkaz:
https://doaj.org/article/467e25f2bae44a0d9fc1ab6d38d23b26
Autor:
Jihad Georges, Youssef, Philip, Lavin, David A, Schoenfeld, Richard A, Lee, Rainer, Lenhardt, David J, Park, Javier Perez, Fernandez, Melvin L, Morganroth, Jonathan C, Javitt, Dushyantha, Jayaweera
Publikováno v:
Critical Care Medicine. 50:1545-1554
Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopat
Autor:
Daniel C. Javitt, Jonathan C. Javitt
OBJECTIVEN-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75c40f1a638a151c022ab77bd5bc8db6
https://doi.org/10.1101/2022.08.12.503713
https://doi.org/10.1101/2022.08.12.503713
Autor:
Andrew Nierenberg, Philip Lavin, Daniel C. Javitt, Richard Shelton, Sanjay Matthew, Robert A Besthof, Jonathan C. Javitt
ObjectivesWe tested the hypothesis that after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloserine (DCS) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abb16d0101f34db3818239d10949485a
https://doi.org/10.1101/2022.08.11.22278658
https://doi.org/10.1101/2022.08.11.22278658
Publikováno v:
TP48. TP048 COVID: ARDS CLINICAL STUDIES.
Purpose: To assess the clinical safety and possible effectiveness of Vasoactive Intestinal Peptide in the treatment of Acute Respiratory Distress Syndrome (ARDS) related to sepsis.Methods: Under FDA Investigational New Drug clearance, 8 patients with
Autor:
J.G. Youssef, Mukhtar Al-Saadi, J.A. Kelly, G. Youssef, Sarah Beshay, Matthew J. Javitt, M. Syed, Jonathan C. Javitt, M. Bitar, F. Zahiruddin
Publikováno v:
TP48. TP048 COVID: ARDS CLINICAL STUDIES.
Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect Alveolar Type II cells by blocking replication of the SARS-CoV-2 virus, inhibiting cytokine synthesis, preventing cytopathy, and upregulating surfactant production. RLF-1
Autor:
Park Dj, Fernandez Jp, Jonathan C. Javitt, J.G. Youssef, Lavin P, Jayaweera D, Morganroth M, Lenhardt R, Lee R
Publikováno v:
SSRN Electronic Journal.
Background: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive Intestinal Peptide (VIP) has been granted Emergency Use Authorization and or Compassionate Care Authorization in multiple cou
Autor:
J.G. Youssef, Jonathan C. Javitt
Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect the Alveolar Type II cell by blocking replication of the SARS-CoV-2 virus, upregulating surfactant production, blocking apoptosis, and blocking cytokine effects. RLF-100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ab88019ff4c25456262eaddf36c2a1